Ubs Group Ag Alterity Therapeutics LTD Transaction History

Ubs Group Ag

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$0.01 - $0.02 $104 - $209	-10,487 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$0.01 - $0.02 $31 - $62	-3,112 Reduced 22.88%	10,487 $9,000
Q4 2021 Feb 14, 2022	BUY	$0.01 - $0.02 $135 - $271	13,599 New	13,599 $10,000
Q3 2021 Nov 15, 2021	SELL	$0.02 - $0.03 $93 - $139	-4,658 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$0.02 - $0.03 $91 - $137	4,588 Added 6554.29%	4,658 $6,000
Q1 2021 May 12, 2021	SELL	$0.02 - $0.03 $36 - $55	-1,845 Reduced 96.34%	70 $0
Q4 2020 Feb 11, 2021	BUY	$0.01 - $0.05 $16 - $83	1,677 Added 704.62%	1,915 $3,000
Q3 2020 Nov 12, 2020	SELL	$0.0 - $0.05 $0 - $2,643	-52,876 Reduced 99.55%	238 $0
Q2 2020 Jul 31, 2020	BUY	$0.0 - $0.03 $0 - $1,501	50,037 Added 1626.16%	53,114 $63,000
Q1 2020 May 01, 2020	BUY	$0.01 - $0.07 $30 - $210	3,007 Added 4295.71%	3,077 $2,000
Q4 2019 Feb 14, 2020	SELL	$0.01 - $0.02 $22 - $45	-2,282 Reduced 97.02%	70 $0
Q3 2019 Nov 14, 2019	SELL	$0.0 - $0.02 $0 - $79	-3,987 Reduced 62.9%	2,352 $3,000
Q2 2019 Aug 14, 2019	BUY	$0.0 - $0.03 $0 - $190	6,339 New	6,339 $8,000

Ticker ATHE
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,114,600
Market Cap $59.4M
Description
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.